These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 6601143)

  • 1. Comparative structural analysis of HLA-A2 antigens distinguishable by cytotoxic T lymphocytes. II. Variant DK1: evidence for a discrete CTL recognition region.
    Krangel MS; Biddison WE; Strominger JL
    J Immunol; 1983 Apr; 130(4):1856-62. PubMed ID: 6601143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative structural analysis of HLA-A3 antigens distinguishable by cytotoxic T lymphocytes: variant E1.
    van Schravendijk MR; Biddison WE; Berger AE; Coligan JE
    J Immunol; 1985 Jan; 134(1):410-6. PubMed ID: 3871112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural analysis of HLA-A2 antigen from immunoselected mutant 8.6.1: further definition of an HLA-A2-specific serological determinant.
    Taketani S; Krangel MS; Pious D; Strominger JL
    J Immunol; 1983 Dec; 131(6):2935-8. PubMed ID: 6196407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural analysis of an HLA-B7 antigen variant detected by cytotoxic T lymphocytes.
    Taketani S; Krangel MS; Spits H; de Vries J; Strominger JL
    J Immunol; 1984 Aug; 133(2):816-21. PubMed ID: 6429245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular analysis of an HLA-A2 functional variant CLA defined by cytolytic T lymphocytes.
    Ezquerra A; Doménech N; van der Poel J; Strominger JL; Vega MA; López de Castro JA
    J Immunol; 1986 Sep; 137(5):1642-9. PubMed ID: 3489037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of amino acid substitutions in the beta-sheet floor and alpha-2 helix of HLA-A2 on recognition by alloreactive viral peptide-specific cytotoxic T lymphocytes.
    Mattson DH; Shimojo N; Cowan EP; Baskin JJ; Turner RV; Shvetsky BD; Coligan JE; Maloy WL; Biddison WE
    J Immunol; 1989 Aug; 143(4):1101-7. PubMed ID: 2473117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A panel of unique HLA-A2 mutant molecules define epitopes recognized by HLA-A2-specific antibodies and cytotoxic T lymphocytes.
    Hogan KT; Clayberger C; Bernhard EJ; Walk SF; Ridge JP; Parham P; Krensky AM; Engelhard VH
    J Immunol; 1989 Mar; 142(6):2097-104. PubMed ID: 2466083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural identity between HLA-A2 antigens differentially recognized by alloreactive cytotoxic T lymphocytes.
    Castaño AR; Lauzurica P; Domenech N; López de Castro JA
    J Immunol; 1991 May; 146(9):2915-20. PubMed ID: 2016531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification by site-directed mutagenesis of amino acid residues contributing to serologic and CTL-defined epitope differences between HLA-A2.1 and HLA-A2.3.
    Hogan KT; Clayberger C; Bernhard EJ; Walk SF; Ridge JP; Parham P; Krensky AM; Engelhard VH
    J Immunol; 1988 Oct; 141(7):2519-25. PubMed ID: 2459215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clonal T lymphocyte recognition of the fine structure of the HLA-A2 molecule.
    Brenner MB; McLean J; Yang SY; van der Poel JJ; Pious D; Strominger JL
    J Immunol; 1985 Jul; 135(1):384-90. PubMed ID: 2582041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delineation of functional sites in HLA-B27 antigens. Molecular analysis of HLA-B27 variant Wewak I defined by cytolytic T lymphocytes.
    Vega MA; Wallace L; Rojo S; Bragado R; Aparicio P; López de Castro JA
    J Immunol; 1985 Nov; 135(5):3323-32. PubMed ID: 3930603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delineation of immunologically and biochemically distinct HLA-A2 antigens.
    Biddison WE; Kostyu DD; Strominger JL; Krangel MS
    J Immunol; 1982 Aug; 129(2):730-4. PubMed ID: 6177780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection.
    Nayersina R; Fowler P; Guilhot S; Missale G; Cerny A; Schlicht HJ; Vitiello A; Chesnut R; Person JL; Redeker AG; Chisari FV
    J Immunol; 1993 May; 150(10):4659-71. PubMed ID: 7683326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative structural analysis of HLA-A2 antigens distinguishable by cytotoxic T lymphocytes: variants M7 and DR1.
    Krangel MS; Taketani S; Biddison WE; Strong DM; Strominger JL
    Biochemistry; 1982 Nov; 21(24):6313-21. PubMed ID: 6983890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
    Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P
    Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular cloning and DNA sequence analysis of genes encoding cytotoxic T lymphocyte-defined HLA-A3 subtypes: the E1 subtype.
    Cowan EP; Jordan BR; Coligan JE
    J Immunol; 1985 Oct; 135(4):2835-41. PubMed ID: 2993417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 45 pocket of HLA-A2.1 plays a role in presentation of influenza virus matrix peptide and alloantigens.
    Winter CC; Carreno BM; Turner RV; Koenig S; Biddison WE
    J Immunol; 1991 May; 146(10):3508-12. PubMed ID: 2026879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 707-AP peptide recognized by human antibody induces human leukocyte antigen A2-restricted cytotoxic T lymphocyte killing of melanoma.
    Takahashi T; Irie RF; Nishinaka Y; Hoon DS
    Clin Cancer Res; 1997 Aug; 3(8):1363-70. PubMed ID: 9815820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recognition of human melanoma cells by HLA-A2.1-restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes.
    Slingluff CL; Cox AL; Henderson RA; Hunt DF; Engelhard VH
    J Immunol; 1993 Apr; 150(7):2955-63. PubMed ID: 7681084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
    Zaremba S; Barzaga E; Zhu M; Soares N; Tsang KY; Schlom J
    Cancer Res; 1997 Oct; 57(20):4570-7. PubMed ID: 9377571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.